Previous studies have shown that biomarkers, such as PD-L1 [18], TMB [20], and tumor-infiltrating lymphocytes (TILs) [30], can reflect the immunological landscape and predict immunotherapy responses in NPC. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.